Asset profile
Ravulizumab · Ultomiris
Monoclonal antibody
Evidence outlook
Approved: adult and pediatric patients one month of age and older with paroxysmal nocturnal... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 1 direct rival (same mechanism and indication), 4 same-class, 60 same-indication; 26 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ravulizumab (Ultomiris): this drug | Phase 3 | Monoclonal antibody | Complement C5 | ||
| Eculizumab (Soliris) | Phase 3 | Monoclonal antibody | Complement C5 | ||
| Avacincaptad Pegol (Izervay) | Approved | Rna Aptamer | Complement C5 | ||
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | ||
| Pozelimab | Phase 3 | Monoclonal antibody | Complement C5 | ||
| ABBV-6628 | Phase 1/2 | Antibody fragment | Complement C5 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (5)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (2)
November 2027 (1)
What to watch
2028 (3)
September 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2030 (1)
January 2030 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.